Boehringer’s HER2-mutated lung cancer drug shows sustained benefit for 14 months
Boehringer Ingelheim’s drug candidate for human epidermal growth factor receptor 2 (HER2)-mutated non-small cell lung cancer (NSCLC) has demonstrated a…
News
Pacira’s gene therapy shows sustained benefits in trial for knee osteoarthritis
Kura doses first subjects in trial of ziftomenib for advanced GIST
New data from J&J’s bladder cancer drug-device trial strengthens support for NDA
US FDA approves BlackfinBio’s gene therapy trial for hereditary spastic paraplegia
ALX Oncology’s CD47-blocker and Keytruda combo fails in two Phase II trials
Kardium reports strong PFA system trial results
Pfizer’s sasanlimab and BCG combo therapy improves EFS in bladder cancer trial
